Muscle carnosine is associated with cardiometabolic risk factors in humans

Barbora de Courten, Timea Kurdiova, Maximilian Pangratius J De Courten, Vitazoslav Belan, Inge Everaert, Marek Vician, Helena Jane Teede, Daniela Gasperikova, Giancarlo Aldini, Wim Derave, Jozef Ukropec, Barbara Ukropcova

Research output: Contribution to journalArticleResearchpeer-review

29 Citations (Scopus)


Background Carnosine is a naturally present dipeptide abundant in skeletal muscle and an over-the counter food additive. Animal data suggest a role of carnosine supplementation in the prevention and treatment of obesity, insulin resistance, type 2 diabetes and cardiovascular disease but only limited human data exists. Methods and Results Samples of vastus lateralis muscle were obtained by needle biopsy. We measured muscle carnosine levels (high-performance liquid chromatography), body fat (bioimpedance), abdominal subcutaneous and visceral adiposity (magnetic resonance imaging), insulin sensitivity (euglycaemic hyperinsulinemic clamp), resting energy expenditure (REE, indirect calorimetry), free-living ambulatory physical activity (accelerometers) and lipid profile in 36 sedentary non-vegetarian middle aged men (45?7 years) with varying degrees of adiposity and glucose tolerance. Muscle carnosine content was positively related to body fat (r = 0.35, p = 0.04) and subcutaneous (r = 0.38, p = 0.02) but not visceral fat (r = 0.17, p = 0.33). Muscle carnosine content was inversely associated with insulin sensitivity (r = -0.44, p = 0.008), REE (r = -0.58, p
Original languageEnglish
Pages (from-to)1 - 12
Number of pages12
JournalPLoS ONE
Issue number10 (Art. No: e13870)
Publication statusPublished - 2015

Cite this